Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EMBC
stocks logo

EMBC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
258.07M
-1.46%
0.670
+3.08%
261.26M
+0.87%
0.667
-4.64%
282.72M
-4.33%
0.858
-23.44%
Estimates Revision
The market is revising Downward the revenue expectations for Embecta Corp. (EMBC) for FY2026, with the revenue forecasts being adjusted by -0.25% over the past three months. During the same period, the stock price has changed by -21.93%.
Revenue Estimates for FY2026
Revise Downward
down Image
-0.25%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-2.2%
In Past 3 Month
Stock Price
Go Down
down Image
-21.93%
In Past 3 Month
Wall Street analysts forecast EMBC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EMBC is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast EMBC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EMBC is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.680
sliders
Low
25.00
Averages
25.00
High
25.00
Current: 11.680
sliders
Low
25.00
Averages
25.00
High
25.00
BofA
BofA
Underperform
downgrade
$18 -> $11
2025-08-08
Reason
BofA
BofA
Price Target
$18 -> $11
2025-08-08
downgrade
Underperform
Reason
BofA lowered the firm's price target on Embecta to $11 from $18 and keeps an Underperform rating on the shares. The firm notes the company's Q3 revenue of $296M was $17M better than Street's $278M driven by ordering timing benefit from distribution stocking ahead of July 4th holiday, incremental stocking related to brand transition and $7M favorable pricing driven by year-to-date rebate reserve adjustments in the U.S. In Q4, Embecta expects revenues to step down to $265M as order timing benefit reverses, FX to be a $3M incremental h/w and China revenues decline quarter-over-quarter. BofA remains bearish on the stock as it does not see much revenue growth.
Mizuho
Neutral
downgrade
$13 -> $12
2025-07-16
Reason
Mizuho
Price Target
$13 -> $12
2025-07-16
downgrade
Neutral
Reason
Mizuho lowered the firm's price target on Embecta to $12 from $13 and keeps a Neutral rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
BTIG
Marie Thibault
Buy
maintain
$26 -> $25
2025-05-23
Reason
BTIG
Marie Thibault
Price Target
$26 -> $25
2025-05-23
maintain
Buy
Reason
BTIG analyst Marie Thibault lowered the firm's price target on Embecta to $25 from $26 and keeps a Buy rating on the shares after its Investor Day presentation. The company has reaffirmed its FY25 guidance with long-range targets offered through FY28, the analyst tells investors in a research note. Embecta's lower margin outlook relative to FY25 reflects inflationary headwinds, pricing pressure and incremental tariffs, partially offset by cost improvement programs, the firm added.
Mizuho
Neutral
downgrade
$15 -> $13
2025-05-23
Reason
Mizuho
Price Target
$15 -> $13
2025-05-23
downgrade
Neutral
Reason
Mizuho lowered the firm's price target on Embecta to $13 from $15 and keeps a Neutral rating on the shares following the analyst day. The company's long-term guidance calls for sakes to remain relatively flat through 2028, the analyst tells investors in a research note. The firm says that with the outlook lower than expectations, the shares are now pricing in a worst-case scenario outcomes through long-range plan, which seems overdone.
Mizuho
Anthony Petrone
Hold
Initiates
$15
2025-04-10
Reason
Mizuho
Anthony Petrone
Price Target
$15
2025-04-10
Initiates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Embecta Corp (EMBC.O) is 4.05, compared to its 5-year average forward P/E of 8.40. For a more detailed relative valuation and DCF analysis to assess Embecta Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
8.40
Current PE
4.05
Overvalued PE
11.74
Undervalued PE
5.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
7.04
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.46
Undervalued EV/EBITDA
5.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.04
Current PS
0.00
Overvalued PS
1.44
Undervalued PS
0.65
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

EMBC News & Events

Events Timeline

(ET)
2025-11-25
06:32:56
Embecta projects FY26 adjusted EPS between $2.80 and $3.00, with consensus at $2.95.
select
2025-11-25
06:31:40
Embecta announces Q4 adjusted EPS of 50 cents, surpassing consensus estimate of 46 cents.
select
2025-11-17 (ET)
2025-11-17
17:04:55
Embecta Chairman David Melcher to Step Down, CEO Devdatt Kurdikar to Take Over
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-27CNBC
Midday Stock Highlights: Dell, Arrowhead Pharmaceuticals, Urban Outfitters, and Others

  • Arrowhead Pharmaceuticals: The stock surged 19% after reporting fiscal year revenue of $829.4 million, exceeding analyst expectations, and announcing the first FDA-approved treatment for familial chylomicronemia syndrome.

  • Cleanspark and Kohl's: Cleanspark's shares rose over 4% following a 102% revenue increase to $766.3 million, while Kohl's stock jumped nearly 7% after strong third-quarter earnings and a narrower decline in same-store sales.

  • Embecta and Deere: Embecta's stock fell 6% after disappointing fiscal results, while Deere dropped 5% despite exceeding earnings estimates with $3.93 per share on $10.58 billion in revenue.

  • Nutanix and PagerDuty: Nutanix shares tumbled 15% after missing revenue expectations and lowering its full-year outlook, while PagerDuty's stock plummeted 23% despite beating earnings estimates but falling short on revenue.

[object Object]
Preview
9.5
11-25Newsfilter
Embecta Reports Q4 Revenue of $264M, Down 7.7% Year-over-Year
  • Revenue Decline: Embecta reported Q4 revenue of $264 million, down 7.7% year-over-year, primarily due to advanced distributor orders and ongoing dynamics in the Chinese market, indicating vulnerability amid market fluctuations.
  • Profitability Improvement: Despite the revenue drop, GAAP operating income rose to $56.5 million with a margin of 21.4%, reflecting significant progress in cost control and operational efficiency.
  • Debt Reduction: In Q4 FY2025, Embecta repaid approximately $72.4 million of its term loan, achieving a total debt reduction of about $184.5 million for the year, exceeding the original target of $110 million, thereby enhancing financial flexibility.
  • Future Outlook: The company expects FY2026 revenues to range between $1.071 billion and $1.093 billion, despite facing negative impacts from foreign exchange and the Italian payback measure, demonstrating cautious optimism for future growth.
[object Object]
Preview
8.0
11-25Newsfilter
Embecta Declares $0.15 Quarterly Cash Dividend Per Share
  • Dividend Announcement: Embecta's Board of Directors has declared a quarterly cash dividend of $0.15 per share, payable on December 18, 2025, which aims to reward shareholders and enhance investor confidence.
  • Record Date for Shareholders: The record date for this dividend is set for December 5, 2025, ensuring that shareholders holding shares on this date will receive the dividend, reflecting the company's commitment to shareholder interests.
  • Company Background: With a 100-year legacy in insulin delivery, Embecta is evolving into a broad-based medical supplies company, dedicated to improving lives through innovative solutions and the efforts of approximately 2,000 employees worldwide.
  • Market Positioning: By announcing this dividend, Embecta not only demonstrates its financial stability but also indicates its ongoing strategic development in the medical supplies sector, aiming to attract more investor interest in its long-term growth potential.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Embecta Corp (EMBC) stock price today?

The current price of EMBC is 11.68 USD — it has decreased -2.26 % in the last trading day.

arrow icon

What is Embecta Corp (EMBC)'s business?

Embecta Corp. is a global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It also sells safety insulin syringes. It distributes its products through a variety of channels, including retail, hospitals and pharmacies.

arrow icon

What is the price predicton of EMBC Stock?

Wall Street analysts forecast EMBC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EMBC is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Embecta Corp (EMBC)'s revenue for the last quarter?

Embecta Corp revenue for the last quarter amounts to 264.00M USD, decreased -7.72 % YoY.

arrow icon

What is Embecta Corp (EMBC)'s earnings per share (EPS) for the last quarter?

Embecta Corp. EPS for the last quarter amounts to 0.44 USD, increased 76.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Embecta Corp (EMBC)'s fundamentals?

The market is revising Downward the revenue expectations for Embecta Corp. (EMBC) for FY2026, with the revenue forecasts being adjusted by -0.25% over the past three months. During the same period, the stock price has changed by -21.93%.
arrow icon

How many employees does Embecta Corp (EMBC). have?

Embecta Corp (EMBC) has 1850 emplpoyees as of December 05 2025.

arrow icon

What is Embecta Corp (EMBC) market cap?

Today EMBC has the market capitalization of 683.43M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free